ContractWarrant Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 24th, 2023 Company IndustryTHIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of February [●], 2023, by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”), and Lind Global Fund II LP, a Delaware limited partnership (the “Investor”).
SECURITY AGREEMENTSecurity Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 24th, 2023 Company IndustrySECURITY AGREEMENT (this “Agreement”), dated as of February 23, 2023, by and between ABVC BIOPHARMA, INC., a Nevada corporation (the “Company”), and LIND GLOBAL FUND II LP (the “Secured Party”).
Senior Convertible Promissory Note due August 23, 2024Note • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionFor value received, ABVC BioPharma, Inc., a Nevada corporation (the “Maker” or the “Company”), hereby promises to pay to the order of Lind Global Fund II LP, a Delaware limited partnership (together with its successors and representatives, the “Holder”), in accordance with the terms hereinafter provided, the principal amount of THREE MILLION SEVEN HUNDRED FOUR THOUSAND ONE HUNDRED SIXTY SEVEN DOLLARS ($3,704,167.00) (the “Principal Amount”).
STOCK PLEDGE AGREEMENTStock Pledge Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 24th, 2023 Company IndustryThis PLEDGE AGREEMENT (this “Agreement”) is made as of February 23, 2023, by and between ABVC Biopharma, Inc., a Nevada corporation (the “Company”), and LIND GLOBAL FUND II LP (the “Secured Party”).
GUARANTYGuaranty • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionGUARANTY (the “Guaranty”), dated as of February 23, 2023, by AMERICAN BRIVISION CORPORATION, a Delaware corporation (“American BriVision”), BIOKEY, INC., a California corporation (“BioKey”), BIOLITE HOLDINGS, INC., a Nevada corporation (“BioLite”), and BIOLITE BVI, INC., a British Virgin Islands corporation (“BioLite BVI” and, collectively with American BriVision, BioKey and BioLite, the “Guarantors”, and each, a “Guarantor”), in favor of LIND GLOBAL FUND II LP (the “Lender”).
GUARANTOR SECURITY AGREEMENTGuarantor Security Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 24th, 2023 Company IndustryGUARANTOR SECURITY AGREEMENT (this “Agreement”), dated as of February 23, 2023, by and among AMERICAN BRIVISION CORPORATION, a Delaware corporation (“American BriVision”), BIOKEY, INC., a California corporation (“BioKey”), BIOLITE HOLDING, INC., a Nevada corporation (“BioLite”), BIOLITE BVI, INC., a British Virgin Islands corporation (“BioLite BVI” and, collectively with American BriVision, BioKey and BioLite, the “Companies”, and each, individually, a “Company”), and LIND GLOBAL FUND II LP (the “Secured Party”).
COPYRIGHT SECURITY AGREEMENTCopyright Security Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis COPYRIGHT SECURITY AGREEMENT (this “Patent Security Agreement”) is entered into as of February 23, 2023 by and between ABVC BIOPHARMA, INC., a Nevada corporation (the “Grantor”) and LIND GLOBAL FUND II LP (the “Lender”).
PATENT SECURITY AGREEMENTPatent Security Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis PATENT SECURITY AGREEMENT (this “Patent Security Agreement”) is entered into as of February 23, 2023 by and between ABVC BIOPHARMA, INC., a Nevada corporation (the “Grantor”) and LIND GLOBAL FUND II LP (the “Lender”).
TRADEMARK SECURITY AGREEMENTTrademark Security Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis TRADEMARK SECURITY AGREEMENT (this “Trademark Security Agreement”) is entered into as of February 23, 2023 by and between ABVC BIOPHARMA, INC., a Nevada corporation (“ABVC”), Rgene Corporation, a company incorporated under the laws of Taiwan (“Rgene” and, together with ABVC, each a “Grantor” and together, the “Grantors”), and LIND GLOBAL FUND II LP (the “Lender”).
TRADEMARK SECURITY AGREEMENTTrademark Security Agreement • February 24th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis TRADEMARK SECURITY AGREEMENT (this "Trademark Security Agreement") is entered into as of February 23, 2023 by and between ABVC BIOPHARMA, INC., a Nevada corporation (“ABVC”), BioFirst Corporation, a company incorporated under the laws of Taiwan (“BioFirst” and, together with ABVC, each a “Grantor” and together, the “Grantors”) and LIND GLOBAL FUND II LP (the “Lender”).